王崴等

[摘要] 目的 評(píng)價(jià)帕利哌酮緩釋片和利培酮片治療首發(fā)精神分裂癥的療效和安全性。方法 選取56例首發(fā)精神分裂癥患者為觀察對(duì)象，并將其分為研究組和對(duì)照組各28例。分別給予帕利哌酮緩釋片和利培酮片劑治療，并于治療前和治療后的第1、2、4和8周采用陽(yáng)性與陰性癥狀量表（PANSS）評(píng)定療效，副反應(yīng)量表（TESS）評(píng)定不良反應(yīng)。 結(jié)果 兩組患者治療后陽(yáng)性和陰性癥狀量表總分及各因子分均較治療前下降，差異有統(tǒng)計(jì)學(xué)意義（P<0.01）；研究組治療2周末的PANSS總分及2、4、8周的PANSS陰性評(píng)分低于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.01）；兩組患者8周末臨床治療總有效率分別為78.6%和71.4%，差異無(wú)統(tǒng)計(jì)學(xué)意義（P>0.05）；兩組患者不良反應(yīng)發(fā)生率差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。 結(jié)論 帕利哌酮緩釋片對(duì)精神分裂癥疾病治療效果確定，尤其是在早期顯效和改善陰性癥狀方面優(yōu)于利培酮，且安全性更好。

[關(guān)鍵詞] 帕利哌酮緩釋片；利培酮；首發(fā)精神分裂癥

[中圖分類號(hào)] R749 [文獻(xiàn)標(biāo)識(shí)碼] A [文章編號(hào)] 1674-0742（2014）06（b）-0016-03

[Abstract] Objective To evaluate the efficacy and safety of paliperidone extended-release tablets and risperidone tablets in the treatment of first-episode schizophrenia. Methods 56 cases of first-episode schizophrenia patients were selected as the subjects and divided into study group and the control group with 28 cases in each， and the two groups were given paliperidone extended-release tablets and risperidone tablets treatment， respectively. Positive and Negative Syndrome Scale （PANSS） was used to assess the efficacy before the treatment and at 1， 2， 4， 8 weeks after the treatment； Treatment Emergent Symptom Scale（TESS） was used to evaluate the adverse reactions. Results After treatment， the PANSS total scores and factor scores of both groups of patients were lower than those before treatment， the differences were statistically significant（P<0.01）；the PANSS total score 2 weeks after the treatment and the PANSS negative score 2，4，8 weeks after the treatment of the study group were lower than those of the control group， the differences were statistically significant（P<0.01）； the clinical total effective rate 8 weeks after the treatment of the two groups was 78.6%， 71.4%， respectively， the difference was not statistically significant（P>0.05）； the difference in incidence of adverse reactions between two groups was statistically significant（P<0.05）. Conclusion The effect of paliperidone extended-release tablets for the treatment of schizophrenia disease is definite， and it is better than risperidone especially in taking effect early and improving negative symptoms with better safety.

[Key words] Paliperidone extended-release tablets； Risperidone； First-episode schizophrenia

精神分裂癥作為一種病程遷延、致殘率較高及慢性化的精神疾病，給患者的正常生活及工作帶來(lái)嚴(yán)重影響。目前臨床上精神分裂癥的治療強(qiáng)調(diào)全病程治療，其中藥物治療顯得尤為重要，非典型性抗精神病藥物通常作為首選[1]。帕利哌酮緩釋片作為臨床上一種新型非典型抗精神病藥物，于2009年在我國(guó)上市，其主要成分為利培酮的活性代謝產(chǎn)物9—羥基利培酮?？紤]到帕利哌酮緩釋片與利培酮片化學(xué)結(jié)構(gòu)上的相似性，該研究選取該院2012年8月—2013年6月住院的首發(fā)精神分裂癥患者為研究對(duì)象，利用利培酮作為對(duì)照藥物，評(píng)價(jià)帕利哌酮緩釋片治療首發(fā)精神分裂癥的療效和安全性，現(xiàn)報(bào)道如下。endprint